<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00010335</url>
  </required_header>
  <id_info>
    <org_study_id>1353.00</org_study_id>
    <secondary_id>FHCRC-1353.00</secondary_id>
    <secondary_id>199/15575</secondary_id>
    <nct_id>NCT00010335</nct_id>
  </id_info>
  <brief_title>Pilot Study of Total Body Irradiation in Combination With Cyclophosphamide, Anti-thymocyte Globulin, and Autologous CD34-Selected Peripheral Blood Stem Cell Transplantation in Children With Refractory Autoimmune Disorders</brief_title>
  <official_title>A Pilot Study of High-Dose Immunosuppression Followed by Infusion of CD34-Selected Autologous or Syngeneic Peripheral Blood Stem Cells for Treatment of Refractory Autoimmune Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      OBJECTIVES: I. Determine the safety and long term complications of total body irradiation in&#xD;
      combination with cyclophosphamide, anti-thymocyte globulin, and autologous CD34-selected&#xD;
      peripheral blood stem cell (PBSC) transplantation in children with refractory autoimmune&#xD;
      disorders.&#xD;
&#xD;
      II. Determine the efficacy of this treatment regimen in these patients. III. Determine the&#xD;
      reconstitution of immunity after autologous CD34-selected PBSC transplantation in these&#xD;
      patients.&#xD;
&#xD;
      IV. Determine engraftment of autologous CD34-selected PBSC in these patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE: This is a multicenter study. Patients receive filgrastim (G-CSF)&#xD;
      subcutaneously daily until peripheral blood stem cell (PBSC) collection is completed. CD34+&#xD;
      cells are separated from the rest of the PBSCs.&#xD;
&#xD;
      Patients undergo total body irradiation twice daily on days -5 and -4. Patients receive&#xD;
      anti-thymocyte globulin IV on days -5, -3, -1, 1, 3, and 5 and cyclophosphamide IV on days -3&#xD;
      and -2. CD34-selected PBSCs are reinfused on day 0. Patients receive G-CSF IV daily beginning&#xD;
      on day 0 and continuing until blood counts recover.&#xD;
&#xD;
      Patients are followed annually for 5 years and then every 5 years thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2000</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>Annually for 5 years and then every 5 years thereafter</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immune reconstitution, engraftment, efficacy, late-effects</measure>
    <time_frame>Annually for 5 years and then every 5 years thereafter</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Systemic Sclerosis</condition>
  <condition>Systemic Lupus Erythematosus</condition>
  <condition>Dermatomyositis</condition>
  <condition>Juvenile Rheumatoid Arthritis</condition>
  <condition>Autoimmune Diseases</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a stem cell transplant.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stem Cell Transplantation</intervention_name>
    <description>Participants will receive a stem cell transplantation along with irradiation and the drugs anti-thymocyte globulin, cyclophosphamide, and filgrastim as noted in the text of this record.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CD34 selection</intervention_name>
    <description>CD34+ cells are separated from the rest of the peripheral blood stem cells.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL ENTRY CRITERIA:&#xD;
&#xD;
        --Disease Characteristics--&#xD;
&#xD;
          -  Diagnosis of 1 of the following based on American College of Rheumatology (ACR)&#xD;
             Criteria: Severe juvenile rheumatoid arthritis (systemic onset or polyarticular&#xD;
             course) Juvenile systemic lupus erythematosus Systemic sclerosis Dermatomyositis&#xD;
&#xD;
          -  Refractory to standard or aggressive therapy OR unacceptable toxicity from standard&#xD;
             therapy&#xD;
&#xD;
          -  Reasonable expectation of possible improvement as evidenced by a good potential for&#xD;
             rehabilitation therapy and adequate social factors&#xD;
&#xD;
          -  No serious CNS damage that would preclude significant functional recovery&#xD;
&#xD;
        --Prior/Concurrent Therapy--&#xD;
&#xD;
          -  Chemotherapy: At least 4 weeks since prior methotrexate or cyclophosphamide&#xD;
&#xD;
          -  Endocrine therapy: At least 4 weeks since prior intra-arterial steroids Juvenile&#xD;
             rheumatoid arthritis patients should continue steroids without taper throughout&#xD;
             mobilization and harvest of stem cells If receiving corticosteroids, must be continued&#xD;
             without taper&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  At least 4 weeks since prior anti-inflammatory agents such as non-steroidal&#xD;
             anti-inflammatory drugs (NSAIDs) or sulfasalazine&#xD;
&#xD;
          -  At least 4 weeks since prior cyclosporine, tacrolimus, mycophenolate mofetil,&#xD;
             azathioprine, penicillamine, or etanercept&#xD;
&#xD;
        --Patient Characteristics--&#xD;
&#xD;
          -  Life expectancy: At least 30 days&#xD;
&#xD;
          -  Hematopoietic: Absolute neutrophil count at least 1,000/mm3 OR Platelet count at least&#xD;
             100,000/mm3 No bone marrow aspirate or biopsy consistent with production defect&#xD;
             (depletion of neutrophil precursors or megakaryocytes) No myelodysplasia&#xD;
&#xD;
          -  Hepatic: Bilirubin no greater than 2.5 mg/dL AST no greater than 300 U/L on two&#xD;
             sequential tests No severe liver dysfunction within past month No active hepatitis A,&#xD;
             B, or C&#xD;
&#xD;
          -  Renal: No end-stage glomerulonephritis or renal disease Creatinine clearance at least&#xD;
             40 mL/min&#xD;
&#xD;
          -  Cardiovascular: No uncontrolled malignant arrhythmia No New York Heart Association&#xD;
             class III or IV congestive heart failure Ejection fraction at least 50%&#xD;
&#xD;
          -  Pulmonary: DLCO at least 45% (DLCO at least 70% for patients with pulmonary disease&#xD;
             caused by documented processes other than primary autoimmune disorder, such as&#xD;
             infectious pneumonia or aspiration pneumonia) No severe pulmonary hypertension (PAP&#xD;
             greater than 50) without potential for significant improvement&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No medical or psychosocial reasons that would make hematopoietic stem cell collection&#xD;
             intolerable&#xD;
&#xD;
          -  No increased anesthetic risks&#xD;
&#xD;
          -  No fever higher than 39 degrees C&#xD;
&#xD;
          -  No positive serology for toxoplasmosis&#xD;
&#xD;
          -  No active life threatening infection not responsive to therapy&#xD;
&#xD;
          -  No other disease or organ dysfunction that would limit survival&#xD;
&#xD;
          -  No known hypersensitivity to murine or equine proteins&#xD;
&#xD;
          -  No known primary immunodeficiency disease HIV negative&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ann Woolfrey</last_name>
    <role>Study Chair</role>
    <affiliation>Fred Hutchinson Cancer Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carol A. Wallace, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>February 2, 2001</study_first_submitted>
  <study_first_submitted_qc>February 1, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2001</study_first_posted>
  <last_update_submitted>March 4, 2015</last_update_submitted>
  <last_update_submitted_qc>March 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>arthritis &amp; connective tissue diseases</keyword>
  <keyword>dermatomyositis</keyword>
  <keyword>immunologic disorders and infectious disorders</keyword>
  <keyword>juvenile rheumatoid arthritis</keyword>
  <keyword>rare disease</keyword>
  <keyword>systemic lupus erythematosus</keyword>
  <keyword>systemic sclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Dermatomyositis</mesh_term>
    <mesh_term>Arthritis, Juvenile</mesh_term>
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
    <mesh_term>Autoimmune Diseases</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

